Two alemtuzumab and three Thymoglobulin patients suffered rejection episodes.

阿仑单抗组有2例而抗胸腺细胞球蛋白组有3例发生排斥反应.

互联网

Alemtuzumab, a humanized anti - CD 52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression.

阿仑单抗, 一种人源性 抗 -CD52抗体, 在免疫耐受诱导方案中效果显著, 需要最少的免疫抑制维持药物.

互联网